

# The comparison between combination of pancreatic stent and nsaid with nsaid alone in preventing post ERCP pancreatitis

## Abstract

ERCP as a diagnostic and therapeutic tool for biliary tract and pancreatic diseases is associated with many complications such as Pancreatitis, bleeding, perforation, and cardiovascular consequences. A recent survey showed that the use of non-steroid anti-inflammatory drugs before ERCP could reduce risk of pancreatitis after ERCP. In order to assess this hypothesis in the patients admitted to Taleghani hospital, Tehran, Iran, with CBD stone, we designed the current study. After randomized selection and division of the patients to different groups; the patient's candidate for pancreatic duct stent (PD stent) and Indomethacin-supplement procedure and the patients under Indomethacin-supplement process alone. After evaluating different variabilities as sex, age, Post ERCP Pancreatitis (PEP) with use of PD stent, PEP with use of indomethacin-supplement and PD stent, medications, type of disease, laboratory test such as CBC, AST, ALT and bilirubin test, ERCP was conducted by one expert specialist. Blinding of the staff and analysis department was conducted as well. Data analysis showed that <10 minutes of cannulation could decrease the incidence of PEP in our study (P-value<0.05), while other variables did not manifested any correlation with the incidence of PEP. In conclusion, we showed the evidence that different interventional elements or patient associated risk factors had no significantly effect on PEP incidence. However, deep cannulation time as the important factor of procedure could alter the rate of PEP.

**Keywords:** post ercp pancreatitis, pancreatic duct stent, indomethacin

Special Issue - 2018

Alizadeh Arash Heidarneshad, Amir  
Houshang Mohammad

Department of Medical Science, University of Shahid Beheshti,  
Iran

**Correspondence:** Mohammad Alizadeh AH, Department  
of Medical Science, University of Shahid Beheshti, Taleghani  
Hospital, Parvaneh Ave, Tabnak Str, Evin, Tehran, Iran-  
1985717413, Tel 0098-21-22432521, Fax 0098-21-22432517,  
Email ahmaliver@yahoo.com

**Received:** May 26, 2017 | **Published:** September 19, 2018

**Abbreviations:** PEP, post ercp pancreatitis; ERCP, endoscopic retrograde cholangio pancreatography

## Introduction

Endoscopic retrograde cholangio pancreatography (ERCP) is one of the safest and most effective procedures that applied frequently in the management of pancreatobiliary disorders.<sup>1</sup> Wide range of complications depending on the type of intervention used, still remain after ERCP. The most important complications of this procedure could be infectious, hemorrhage, perforation and post-ERCP pancreatitis (PEP).<sup>2,3</sup> One of the most common complications is acute pancreatitis that imposes major problems such as morbidity, occasional death and increasing of health care expenditures to the patients.<sup>4,5</sup>

The occurrence of post-ERCP pancreatitis ranges in different studies depending on patient selection, reported from 1-15.7%, however this amount at high-risk patients reaches to 30%.<sup>6-8</sup> the mechanisms that lead to post-ERCP pancreatitis are complex and not fully understood. Rather than having a single pathogenesis, post-ERCP pancreatitis is believed to be multi-factorial, involving a combination of chemical, hydrostatic, enzymatic, mechanical, and thermal factors. Although there are some uncertainties in predicting which patients would develop acute pancreatitis following ERCP, a number of risk factors acting independently or in concert have been proposed as predictors of post-ERCP pancreatitis.<sup>9-12</sup>

Preventing pancreatitis after ERCP remains an important clinical issue. Progress in the last two decades has led to substantive reductions in PEP rates due to more appropriate patient selection, improved procedural techniques, and the adoption of prophylactic pancreatic

duct (PD) stent in high-risk cases. Pancreatic duct stones are found in 22 to 60percent of patients with chronic pancreatitis. The stones can lead to obstruction of outflow of pancreatic secretions, causing increased intraductal pressure. Because the pancreas is relatively noncompliant, the rise in intraductal pressure can induce tissue hypertension and ischemia, which may be a major factor causing pain in patients with chronic pancreatitis.<sup>13-18</sup>

PD stent placement, introduced in the late 1990s, has become a common clinical practice in the United States and is widely regarded as an effective means of preventing PEP in high-risk cases. While PD stent placement clearly reduces risk, it remains technically challenging, time consuming, and costly. Moreover, attempting to place a PD stent with subsequent failure actually increases the risk of PEP above baseline by inducing injury to the pancreatic orifice.<sup>19-24</sup>

A recent survey showed that the use of non-steroid anti-inflammatory drugs before ERCP could reduce the risk of pancreatitis after ERCP. The physiopathology of Indomethacin induced pancreatitis has not yet been elucidated but, as suggested by Memis it probably implicates a decrease in glutathione levels, a decrease in superoxide activities and increased oxidative stress.<sup>25</sup> Different studies were performed to find solutions for prevention of PEP, however no method and medication for reducing PEP effects has been definitively proven yet. Wire-guided biliary cannulation, placement of a pancreatic duct stent and pharmacotherapy are the most important preventive methods which have been discussed. Conflicting reports about the use of each of these methods is reported. It was confirmed that placing stent in pancreatic tracts can play a decisive role in reducing the severity of pancreatitis after ERCP in high risk patients.<sup>26,27</sup>

Several studies have demonstrated that NSAIDs can reduce complications of ERCP. In a report in Iran determine that PEP has no preventive effect for allopurinol. Dr SotoudeManesh showed that beneficial effect of 100mg Indomethacin in prevention of PEP. Cheon Y have shown that younger age (<65years) and female sex were significantly associated with an increased risk of PEP. There is no study at this subject in Iran. So in this study we tried to consider the prophylactic role and evaluation of pancreatic duct stent compared with rectal Indomethacin administration in reducing PEP.

## Material and methods

### Patient screening and selection

Every patient with CBD stone who refer to Taleghani hospital for ERCP was considered to the current study. All patients were divided into two groups applying a randomized method: The patients under PD stent and Indomethacin-supplement procedure in versus the patients under Indomethacin-supplement process. Clinical and demographic characterized of every patients was registered in a questioner. Laboratory tests including: biochemical test (ALT, AST, bilirubin), immunological test such as C-reactive protein (CRP), total blood count (CBC) was performed before the procedure on selected patients. Also, the serum amylase and lipase level was measured 24h after performing ERCP again.

### ERCP procedure and follow up

Post ERCP pancreatitis (PEP) was defined as persistent abdominal

pain in accordance with pancreatitis along with serum amylase or lipase increased 3-fold ( $\geq 3$ ), 24hours after ERCP.

### Blinding evaluation of the patients

Analysis department staffs were blinded due to their unawareness of the patient's subgroup.

### Statistical analysis

Statistical analysis was conducted by SPSS (version 21, Co Ltd, Tokyo, Japan). Differences between groups were considered to be significant if p-values were less than 0.05. Significant association was estimated using chi square or fisher exact tests in pre and post ERCP procedure results.

## Results

### Evaluation of probable patient-related risk factors

After the administration of the selected patients to the study their related risk factors and probable relationship with the incidence of PEP was considered. As shown in Table 1, age, sex, smoking, alcoholism, addiction to opium, abdominal pain, past cholecystectomy, history of PEP, diabetes and chronic pancreatitis were taken by the history patients and their family provided by documents. As mentioned, the patients were subdivided into the groups using a randomized excel method. Then, their risk factors were compared between the groups manifesting no significant relation between any of the variabilities and the risk of PEP.

**Table 1** Of patient-related risk factors in subgroups and relationship them with incidence of PEP. The frequency

Variables	Biliary stent	PD stent	Indomethacin+PD Stent	Total of patients	Incidence of PEP	P value
Female/male	29/31	53/47	92/108	92/108	13/17	0.241
Smoker(yes/no)	19/41	28/74	58/142	86/114	21-Sep	0.522
Age(<60years/>60years)	19/11	48/52	98/102	98/102	19/11	0.437
Alcoholism (yes/no)	Mar-57	May-95	8/192	8/192	27-Mar	0.263
Opium addict(yes/no)	21/29	24/76	38/162	38/162	14/16	0.546
Abdominal pain(yes/no)	36/34	65/35	92/108	92/108	26/4	0.072
Cholecystectomy (yes/no)	26/34	25/75	46/154	46/154	15/15	0.758
History of PEP(yes/no)	Jun-44	8/192	19/181	19/181	22-Aug	0.638
DM(yes/no)	Dec-38	26/74	38/162	38/162	21-Sep	0.462
Chronic-pancreatitis(yes/no)	Jun-54	7/193	2/198	2/198	27-Mar	0.568
Cardiopulmonary (yes/no)	Nov-49	Jun-94	17/183	17/183	27-Mar	0.865

\*=significant association

Note The number of patients in each group is as follows, biliary stent (n=60), PD stent + indomethacin (n=100), total of patients (n=200) and incidence of PEP (n=30)

### Laboratory findings of subgroups before ERCP procedure

In order to understand the probable differences between the laboratory tests of the patients before any ERCP procedure, all the patients were evaluated by their blood sample. The staff taking the blood samples was unaware of the patient's subgroup. Samples were analyzed by the laboratory department of the hospital for AST, ALT, the ratio AST/ALT, HB, WBC, CRP and PALT, showing no significant

difference between the lab data of PEP incidences and non-PEP patients group (Table 2).

### Consideration of applied interventional variables and PEP occurrence rate

Due to the possible effect of different interventional methods or time of procedure, we asses applied procedural methods as biliary stent used patients, PD with/without indomethacin administration groups, PD guide wire, the time of deep cannulation, balloon dilation of S.O.

and biliary sphincterotomy incidence relation with PEP incidence (Table 3). Data analysis revealed <10minutes of deep cannulation significant impact on reducing the incidence of PEP (p-value<0.05). The other interventional factors did not proved any significant relation due to the occurrence of PEP. These data may suggest that being an expert and fast operating specialist as the conductor of the procedure could decrease the incidence of PEP, while other elements of the interventions did not alter the incidence.

**Table 2** The mean comparison of pre ERCP laboratory findings variables between subgroups (mean ±S.E.M)

Variables	PEP	Without PEP	P-value
ALT	117.82±19	86±5.3	0.195
AST	98.3±16.8	73.9±4.9	0.087
AST /ALT	1.25±1.1	1.2±0.11	0.64
HB	13.3±0.45	12.6±0.95	0.86
WBC	10.05±1.27	8.9±0.91	0.56
CRP	26.7±8.5	17.4±3.5	0.91
PLAT	245.08±25.5	235.06±7.5	0.83

\*=significant association

Note Incidence of PEP (n=30), individuals without PEP (n=170)

### Regarding ERCP findings of the groups and PEP incidence

Different findings of the ERCP technique were gathered and

**Table 3** The relationship between applied interventional variables and incidence of PEP in patients

Variables	Incidence of pep	P-value	OR	95%CI
<b>Placement of stent</b>				
Biliary stent	13(43.3%)	0.93	0.964	0.39-2.3
PD stent +Rectal Indomethacin	11(36.6%)	0.55	0.74	0.281-1.9
Administration of rectal	19(63.3%)	0.55	1.3	0.5-3.5
<b>Indomethacin</b>				
PD Guide Wire	18(60.0%)	0.2	1.7	0.74-3.9
Time of deep cannulation			-	-
<10min	4(13.3%)	0.005*	3.41	0.9-4.2
10-30 min	9(30.0%)	0.63	1.3	0.6-3.6
>30 min	17(56.6%)	0.33	1.1	0.5-3.3
Balloon dilation of S.O	9(30.0%)	0.6	1.2	0.47-3.1
Biliary sphincterotomy	16(53.3%)	0.82	0.9	0.39-2.1

\*=significant association


Note Incidence of PEP (n=30)

analyzed from different patient groups, comparing with the significant alter in PEP incidence. As shown in Table 4, CBD diameter dilatation, stricture/stone of CBD, PD dilatation or its irregularity, malignancy, CBD cyst, diverticulum were appraised showing no significant correlation with PEP incidence between different groups of the study (Biliary stent, PD stent, Indomethacin +PD stent).

### Laboratory assessment of the patients before ERCP

As demonstrated in Figure 1, laboratory tests of the patients with PEP and without PEP complication did not show any significant relation with any of the tests (AST, ALT, CRP, WBC, HB, and PLAT). This may reveal its ineffective role in pre-operating ERCP and PEP incidence.

**Figure 1** Diagram of mean comparison of pre-ERCP laboratory finding



variables between patients with PEP complication and without it. There were no significance mean differences between serum lab findings including: AST (Aspartate transaminase), ALT (Alanine transaminase), CRP(C- reactive protein), HB (Hemoglobin), WBC (white blood cells) and PLAT (Platelet) between patients with PEP complication and without it.

**Table 4** The frequency of ERCP finding variables in subgroups and correlations these findings with incidence of PEP

Variables	Biliary stent	PD Stent	Indomethacin +PD	Total of I patients	Incidence of PEP	p-value
GB dilation	2(3.3%)	3(3.0%)	7(3.5%)	7(3.5%)	4(13.3%)	0.77
CBD dilatation	43(71.6%)	73(73%)	76(76%)	114(57.0%)	19(63.3%)	0.132
<b>Diameter of CBD dilatation</b>						
<10mm	36(60.0%)	31(31.0%)	58(58.0%)	89(44.5%)	26(86.6%)	0.84
>10mm	32(53.3%)	56(56.0%)	61(61.0%)	117(58.5)	8(26.6%)	
CBD stricture	19(31.6%)	22(22%)	29(29%)	51(25.5%)	16(53.3%)	0.07
CBD stone	32(53.3%)	48(48.0%)	58(58.0%)	106(53.0%)	17(56.6%)	0.35
PD dilatation	10(16.6%)	11(11.0%)	9(9.0%)	20(10.0%)	2(6.6%)	0.62
PD irregularity	3(5%)	7(7%)	6(6%)	13(6.5%)	2(6.6%)	0.93
Malignancy	10(16.6%)	22(22.0%)	25(25.0%)	47(23.9%)	9(30.0%)	0.36
Pancreas	4(6.6%)	9(9.0%)	5(5.0%)	14(7.0%)	4(13.3%)	0.51
CCA	20(12.0%)	4(4.0%)	16(16%)	20(10%)	26(87.0%)	0.69
Ampulory	2(3.3%)	3(3.0%)	4(4.0%)	7(3.5%)	9(30%)	0.4
Diverticulum	4(6.6%)	2(2.0%)	7(7%)	9(4.5%)	5(16.6%)	0.81
CBD cyst	2(3.3%)	3(3.0%)	1(1.0%)	4(2.0%)	0	0.55

\*=significant association

Note The number of patients in each group is as follows, biliary stent (n=60), PD stent +indomethacin(n=100), total of patients(n=200) and incidence of PEP(n=30)

## Discussion

As the most common complication of ERCP, PEP accounts for a huge financial burden to the hospitals and can cause the deterioration of patient's health.<sup>28</sup> Here, we investigated short-term prophylactic PD stent and rectal indomethacin to prevent PEP in patients with different biliary disorders. Our data suggested that the use of prophylactic rectal indomethacin in combination with PD stents has decreased the rate of PEP in the selected patients, however, the outcome was not significantly different from using rectal indomethacin alone.

In relation to patient-related risk factors, previous studies have discussed that being female and younger ages were significant risk factors for PEP.<sup>29</sup> The impact of age seems to be related to protective effect of progressive decline in pancreatic exocrine function by aging.<sup>30</sup> In addition to PEP, overall complications of ERCP were 1.52times higher in women.<sup>29</sup> In contrast, there was no significant association between age or sex and PEP in our study, even slightly higher risk of PEP, but not significant, was observed. Interestingly, lack of association between age and sex and the risk of PEP also has been observed by Cheng et al.<sup>31</sup> In the searching for patient-related risk factors, previous evidences has reported that post-ERCP elevation of inflammatory and biochemical markers could be a potential predictors of PEP.<sup>32</sup> It has been also reported that pre procedure ESR >30mm/hour is a significant factor that can predict increased risk of PEP.<sup>33</sup> Our evaluation of pre-ERCP level of biochemical markers indicated that there was no significant relationship between these markers prior to ERCP and the risk of elevated PEP.

Procedure-related risk factors and subsequent prophylactic strategies are the other side of post-ERCP pancreatitis prevention. Earlier studies have reported biliary sphincterotomy and balloon dilation of S.O. are the risk factors for developing post-ERCP pancreatitis.<sup>34</sup> However, later reports have not mentioned these

variables as significant risk factors of PEP.<sup>29</sup> Although they alternatively added other risk factors, such as cannulation time and periampullary diverticulum, as significantly related to pancreatitis.<sup>29</sup> Our observation suggested that balloon dilation of S.O. and biliary sphincterotomy were not related to higher risk of PEP. Interestingly, our data indicated a direct and significant relationship between increasing of the time of deep cannulation with increased risk of pancreatitis. The best rate of PEP was related to the procedures in which deep cannulation time was under 10 minutes and this was independent of other patient or procedure-related risk factors.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are potent inhibitors of phospholipase A<sup>2</sup>, cyclooxygenase, and neutrophil-endothelial interactions, all believed to play an important role in the pathogenesis of acute pancreatitis.<sup>35,36</sup> A large body of evidence has recommended NSAIDs for preventing PEP, predominantly in high risk cases.<sup>37</sup> On the other hand, PD stent has been introduced as another safe and effective option to prevent PEP if the operation indications are well controlled.<sup>38</sup> Combination prophylaxis by NSAIDs and PD stents has been investigated and the results suggested superior effects of NSAID prophylaxis alone or insignificant difference in comparison to combination prophylaxis.<sup>39,40</sup> Consistently, our data indicated no significant reduction of PEP by combination of rectal indomethacin prophylaxis with PD stent.

## Conclusion

Overall, here we represent the evidence that the most of procedural or patient associated risk factors in developing PEP had not significantly affected the outcome. Still, deep cannulation time as the important part of procedure has the capacity to alter the rate of PEP by a wide range. PD stent as a prophylactic operation should be considered in parallel by other cost beneficent prophylaxis such as pre-ERCP administration of rectal indomethacin.



## Acknowledgements

None.

## Conflict of interest

There is no conflict of interest in any fields of the study.

## References

1. Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. *Gastrointest Endosc.* 2004;59(7):845–864.
2. Mohammad Alizadeh AH, Afzali ES, Behzad C, et al. Is ESR Important for Predicting Post-ERCP Pancreatitis?. *Clin Med Insights Gastroenterol.* 2015;8:23–27.
3. Nicholas M Szary, Firas H Al-Kawas. Complications of endoscopic retrograde cholangiopancreatography: How to avoid and manage them. *Gastroenterol Hepatol (NY).* 2013;9(8):496–504.
4. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. *N Engl J Med.* 1996;335(13):909–918.
5. Choudhary A, Bechtold ML, Arif M, et al. Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review. *Gastrointest Endosc.* 2011;73(2):275–282.
6. Barthet M, Lesavre N, Desjeux A, et al. Complications of endoscopic sphincterotomy: results from a single tertiary referral center. *Endoscopy.* 2002;34(12):991–997.
7. Cotton PB, Garrow DA, Gallagher J, et al. Risk factors for complications after ERCP: a multivariate analysis of 11,497 procedures over 12 years. *Gastrointest Endosc.* 2009;70(1):80–88.
8. Elmunzer BJ, Scheiman JM, Lehman GA, et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. *N Engl J Med.* 2012;366(15):1414–1422.
9. Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: A prospective, multicenter study. *Gastrointest Endosc.* 2001;54(4):425–434.
10. Chi Liang Cheng, Stuart Sherman, James L Watkins, et al. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. *The American Journal of Gastroenterology.* 2006;101:139–147.
11. Mehta SN, Pavone E, Barkun JS, et al. Predictors of post-ERCP complications in patients with suspected choledocholithiasis. *Endoscopy.* 1998;30(5):457–463.
12. Naitoh I, Ohara H, Nakazawa T, et al. Unilateral versus bilateral endoscopic metal stenting for malignant hilar biliary obstruction. *J Gastroenterol Hepatol.* 2009;24(4):552–557.
13. Petrov MS, Savides TJ. Systematic review of endoscopic ultrasonography versus endoscopic retrograde cholangiopancreatography for suspected choledocholithiasis. *Br J Surg.* 2009;96(9):967–974.
14. Romagnuolo J, Bardou M, Rahme E, et al. Magnetic resonance cholangiopancreatography: a meta-analysis of test performance in suspected biliary disease. *Ann Intern Med.* 2003;139(7):547–557.
15. Sherman S, Troiano FP, Hawes RH, et al. Sphincter of Oddi manometry: Decreased risk of clinical pancreatitis with use of a modified aspirating catheter. *Gastrointest Endosc.* 1990;36(5):462–466.
16. Cennamo V, Fuccio L, Zagari RM, et al. Can a wire-guided cannulation technique increase bile duct cannulation rate and prevent post-ERCP pancreatitis: A meta-analysis of randomized controlled trials. *Am J Gastroenterol.* 2009;104(9):2343–2350.
17. Gregory A. Cote, Michael Anstas, Rishi Pawa, et al. Difficult biliary cannulation: use of physician controlled wire-guided cannulation over a pancreatic duct stent to reduce the rate of precut sphincterotomy (with video). *Gastrointest Endosc.* 2010;71(2):275–279.
18. Freeman ML. Pancreatic stents for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. *Clin Gastroenterol Hepatol* 2007;5(11):1354–1165.
19. Brackbill S, Young S, Schoenfeld P, et al. A survey of physician practices on prophylactic pancreatic stents. *Gastrointest Endosc.* 2006;64(1):45–52.
20. Fazel A, Quadri A, Catalano MF, et al. Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study. *Gastrointest Endosc.* 2003;57(3):291–294.
21. Zolotarevsky E, Fehmi SM, Anderson MA, et al. Prophylactic 5-Fr pancreatic duct stents are superior to 3-Fr stents: a randomized controlled trial. *Endoscopy.* 2011;43(4):325–330.
22. Freeman ML, Overby C, Qi D. Pancreatic stent insertion: consequences of failure and results of a modified technique to maximize success. *Gastrointest Endosc.* 2004;59(1):8–14.
23. Mahjoub W, Jarbou S, Ben Moussa M, et al. Indomethacin-induced pancreatitis; a second case report. *JOP.* 2006;7(3):321–323.
24. Drake DH, Fry WJ. Ductal drainage for chronic pancreatitis. *Surgery.* 1989;105(2):131–140.
25. Bradley EL. Pancreatic duct pressure in chronic pancreatitis. *Am J Surg.* 1982;144(3):313–336.
26. Goran Hauser, Marko Milosevic, Davor Stimac, et al. Preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: What can be done? *World J Gastroenterology.* 2015;21(4):1069–1080.
27. Wang P, Li ZS, Liu F, et al. Risk factors for ERCP-related complications: a prospective multicenter study. *Am J Gastroenterology.* 2009;104(1):31–40.
28. Laugier R, Bernard JP, Berthezene P, et al. Changes in pancreatic exocrine secretion with age: pancreatic exocrine secretion does decrease in the elderly. *Digestion.* 1991;50(3–4):202–211.
29. Bulent Güngör, Kasım Çağlaya, Cafer Polat, et al. The predictivity of serum biochemical markers in acute biliary pancreatitis. *ISRN gastroenterology.* 2011;2011:279607.
30. Messmann H, Vogt W, Holstege A, et al. Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis. *Gut.* 1997;40(1):80–85.
31. Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. *Gastrointestinal endoscopy.* 2001;54(4):425–434.
32. Gross V, Leser HG, Heinisch A, et al. Inflammatory mediators and cytokines--new aspects of the pathophysiology and assessment of severity of acute pancreatitis?. *Hepato-gastroenterology.* 1993;40(6):522–530.
33. Mäkelä A, Kuusi T, Schröder T. Inhibition of serum phospholipase-A2 in acute pancreatitis by pharmacological agents in vitro. *Scandinavian journal of clinical and laboratory investigation.* 1997;57(5):401–407.
34. Puig I, Calvet X, Baylina M, et al. How and when should NSAIDs be used for preventing post-ERCP pancreatitis? A systematic review and meta-analysis. *PLoS one.* 2014;9(3):e92922.
35. Fan JH, Qian JB, Wang YM, et al. Updated meta-analysis of pancreatic stent placement in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis. *World J of Gastroenterology.* 2015;21(24):7577–7583.

36. Elmunzer BJ, Higgins PD, Saini SD, et al. Does rectal indomethacin eliminate the need for prophylactic pancreatic stent placement in patients undergoing high-risk ERCP? Post hoc efficacy and cost-benefit analyses using prospective clinical trial data. *Am J Gastroenterology*. 2013;108(3):410–415.
37. Akbar A, Dayyeh BK, Baron TH, et al. Rectal nonsteroidal anti-inflammatory drugs are superior to pancreatic duct stents in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a network meta-analysis. *Clin Gastroenterology and Hepatology*. 2013;11(7):778–783.
38. Freeman ML, Guda NM. Prevention of Post-ERCP Pancreatitis: a comprehensive review. *Gastrointest Endosc*. 2004;59:845–64
39. Choudhary A, Bechtold ML, Arif M, et al. Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review. *Gastrointest Endosc*. 2011;73:275–82.
40. Cheng CL, Sherman S, Watkins JL, et al. Silverman WB. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. *The American journal of gastroenterology*. 2006;101(1):139–47.